DEVELOPMENT OF STRATEGIES FOR PREVENTION OF CHRONIC KIDNEY DISEASE RELEVENT TO DIFFERENT REGIONS AND COUNTRIES ROBERT C ATKINS BELLAGIO, MARCH 2004.

Slides:

Advertisements

Similar presentations

The Burden of Obesity in North Carolina Obesity-Related Chronic Disease.

Advertisements

The National Kidney Foundations Kidney Early Evaluation Program TM The National Kidney Foundations Kidney Early Evaluation Program TM Essex-Passaic Wellness.

Diabetic Nephropathy.  Over 40% of new cases of end-stage renal disease (ESRD) are attributed to diabetes.  In 2001, 41,312 people with diabetes began.

Lysaght, J Am Soc Nephrol, 2002 Number of patients worldwide treated with chronic dialysis from 1990 to ,000 1,490,000 2,500,000.

Chronic renal diseases as a public health problem Epidemiology, Social and Economical Implications Arrigo Schieppati Bellagio March 16, 2004.

Drug therapy in renal failure Kari Laine, MD, PhD University of Turku & medbase Ltd.

World population: 6.7 billion Global Prevalence Patients per million population (p.m.p.) Global View of ESRD Patients World population 1.2% ESRD~ 7% Haemodialysis7-8%

Chronic kidney disease: [insert title here] Insert name, title, date here Insert acknowledgements here.

End Stage Renal Disease in Children. End stage kidney disease occurs when the kidneys are no longer able to function at a level that is necessary for.

The PREVEND Study: Screening for micro-albuminuria

Recent Advances in Management of CRF Yousef Boobess, M.D. Head, Nephrology Division Tawam Hospital.

General Practice Workshop This workshop was conceived and developed by Kidney Health Australia’s Kidney Check Australia Taskforce with particular thanks.

Treatment-Resistant Hypertension: Magnitude of the Problem Power Over Pressure

A retrospective cohort study of Childhood post-streptococcal glomerulonephritis as a risk factor for chronic renal disease in later life Andrew V White,

 Currently 150 Million people worldwide suffering from diabetes and that number may double by the year  The prevalence of type 2 diabetes is dramatically.

Global burden of Diabetes: Prevalence and projections Belllagio, March 16 th 2004 Peter H. Bennett, M.B., F.R.C.P. National Institute of Diabetes and Digestive.

Diabetes Mellitus Type 2

Lesley Stevens MD Tufts-New England Medical Center

Kidney Diseases Prevention. Overview The mortality rate of Nephritis, Nephrotic Syndrome, and Nephrosis (18.15 per 100,000 population) marching the 7th.

Prevalance of Chronic Kidney Disease 26 million people have diagnosed chronic kidney 26 million people have diagnosed chronic kidney disease (CKD) ( National.

Coronary Heart Disease (CHD): A Disease of Affluence.

APPENDIX 1. D-1 New cases of diagnosed diabetes D-2.1 All cause mortality* D-2.2 Cardiovascular disease deaths* D-3 Diabetes death rate, multiple cause.

What is Diabetes? Diabetes is a chronic disease that occurs either when the pancreas does not produce enough insulin or when the body cannot effectively.

Section 1: CKD Epidemiology. The Problem Chronic Kidney Disease is an epidemic worldwide –Growth 6-8% per annum of dialysis patients Accumulating data.

Section 4: Managing progression of CKD. Glomerulosclerosis Reduction in number of functioning glomeruli Increased blood flow to remaining nephrons Intraglomerular.

RENAL DISEASE IN DIABETES

Live Donor Registry Steve Chadban. Transplant numbers.

EPIDEMIOLOGY Epidemiology of chronic kidney injury, including prevalence and prognosis in various community groups. Screening of populations for kidney.

Improving Nephrology around the World March 16-18, 2004 ISN COMGAN Bellagio Conference Prevention of renal diseases in the emerging world: Toward global.

SM Gatmiri, MD, Nephrologist Imam Khomeini Hospital,

HYPERTENSION BURDEN AND CVD RISK PREDICTION IN AFRICA.

Dept. of Nephrology and Immunology San Carlo Borromeo Hospital - Milan Giuseppe D’Amico MD, FRCP OPPORTUNITIES FOR A CHRONIC DISEASE OUTREACH PROGRAM IN.

1. Epidemiology of Type 2 Diabetes Dr Ghadiri Diabetes Primary Goal for 2010 Through prevention programs, reduce the disease incidence, its complications.

Dr M Sivalingam Renal Unit, Lister Hospital, Stevenage.

Healthy People 2010 Focus Area 4

ANZDATA Registry Overview Dr Graeme Russ Darwin September 2001 September 2001.

2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 7: Transplantation.

© ANZDATA Registry Prevalence and Incidence End Stage Renal Failure - Australia ( ) Per Million Functioning Transplant (259) New Pts (82) Deaths.

Part 2. Educational Objectives Upon completion of this activity, participants will be able to Name 5 current challenges for glycemic control in individuals.

2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 13: International Comparisons.

Chronic Kidney Disease (CKD) Healthy Kansans 2010.

Published by : Koncept Analytics Published on : March 2016 Single User License: US $ 800 No of Pages : 49.

1 به نام خدا. Epidemiology of chronic kidney disease 2.

The RAVE Study Renal Athersosclerotic Revascularization Evaluation Reference Tobe SW, Atri M, Perkins N, et al. Renal Athersosclerotic revascularization.

Circulation. 2014;129: Association Between Plasma Triglycerides and High-Density Lipoprotein Cholesterol and Microvascular Kidney Disease and Retinopathy.

Cardiovascular Risk: A global perspective

2016 Annual Data Report, Vol 2, ESRD, Ch 13

Section 1: CKD Epidemiology

Section 4: Managing progression of CKD

DR GHULAM NABI KAZI WHO Country Office Pakistan

Golden Rules to Keep Kidneys Healthy

Odd ratio of developing kidney failure figure 1

2017 Annual Data Report Healthy People 2020.

Volume 2: End-Stage Renal Disease Chapter 6: Transplantation

December 31st point prevalent counts by modality figure 3.1

Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment

End-stage renal disease prevention strategies in Latin America

به نام خدا.

Francesco Paolo Schena Kidney International

Rationale for an International Federation of Kidney Foundations

Chronic Kidney Disease

Anemia as a risk factor for chronic kidney disease

The epidemiology of chronic kidney disease

Lynda Anne Szczech, Ira L. Lazar Kidney International

Worldwide incidence of ESRD figure 12.1, per million population

© 2016 Global Market Insights, Inc. USA. All Rights Reserved Levocarnitine Market predicted to grow exponentially by 2025: Global Market.

A) Annual diagnosed incidence of pulmonary embolism (PE), and b) annual full incidence of chronic thromboembolic pulmonary hypertension (CTEPH) per 100 000.

Trends in the incidence of renal failure in Australia

The Secret Behind Glucose Monitoring Devices Market…

Blood Glucose Device Market. Report Description and Highlights According to International diabetes federation, in 2017, there are around 425 million of.

Presentation transcript:

DEVELOPMENT OF STRATEGIES FOR PREVENTION OF CHRONIC KIDNEY DISEASE RELEVENT TO DIFFERENT REGIONS AND COUNTRIES ROBERT C ATKINS BELLAGIO, MARCH 2004

USA: 283,000 Latin Am: 82,000 Eur: 317,000 India: China: 30,000 AUS/NZL: 11,000 Japan: 167,000 Schena, Kidney Int (Suppl 74), 2000 World-ESRD (1996) Prevalence Incidence 1,000, ,000 DIALYSIS PATIENTS WORLD-WIDE (1996)

Incidence of Diabetes in E.S.R.F Australia Year of Entry Number of DiabeticsNumber of New Patients

 Diabetes and hypertension are the main causes for ESRD in the USA  The proportion of ESRD patients with diabetic nephropathy is higher in the USA than in Europe. However, diabetic nephropathy is the most rapidly growing cause of ESRD in European countries CAUSES OF ESRD IN THE USA Diabetes Hypertension Glomerulonephritis Cystic kidney Incidence rates (x million population) USRDS, 2000

AUSDIAB RESULTS 7.2% with diabetes (3.6% known and 3.6% newly diagnosed) 16.1% with impaired glucose metabolism 60% overweight or obese 61.3% with high cholesterol (7.3% on treatment) 29% with high blood pressure (14% on treatment)

PREVALENCE OF RENAL ABNORMALITIES 1.Haematuria >10x10 6 /L4.6% 2.Proteinuria2.4% UP:UC>0.2 mg/mg 3.Renal Impairment11.2% calculated GFR <60 mls/min No abnormality82% At least one abnormality18% Multiple abnormalities 2%

PREVALENCE OF TYPE 2 DIABETES IN ASIA AND PACIFIC Age-standardised to Segi’s world population years except: * ³40 **30-59 ‡ #20-64 § 40-69

World m 300 m 55 m 72 m Developed Count.Developing Count. 99 m 228 m * In million subjects 47% 116% 25% 140% 150% 102% 64% THE GLOBAL BURDEN OF DIABETES ( )